Discovery STAGE Agents*
Further along the path of precision medicine
Endocyte currently has a prostate-specific membrane antigen (PSMA) targeted drug, a therapeutic for inflammatory diseases, and a therapeutic for the treatment of polycystic kidney disease under development.
EC2319 is a new approach to inflammation therapy, targeting a highly potent anti-folate drug to activated macrophages expressing folate receptors.
EC0371 POLYCYSTIC KIDNEY DISEASE (PKD)
EC0371 is a folate-targeted, water-soluble form of rapamycin that is being developed to selectively inhibit mTOR activity in polycystic kidneys to reduce abnormal growth.
* The safety and efficacy of these agents have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.